Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment
    • Strides to exit...

    Strides to exit investment in Arrow Pharma for over Rs 2000 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-01-30T09:30:23+05:30  |  Updated On 16 Aug 2021 5:47 PM IST

    "Strides will receive AUD 300 million as upfront payment at the closure of the transaction, while the balance AUD 94 million to be deferred through a secured instrument," it added.


    New Delhi: Drug firm Strides Pharma Science Tuesday said it has decided to exit its investment in Arrow Pharmaceuticals for AUD 394 million (over Rs 2,000 crore). The company's step-down subsidiary Strides Pharma Global Pte Ltd has approved the sale of its entire Australian business to the Arrow-Apotex merged entity, Strides Pharma Science said in a filing to the BSE.


    "Strides will receive AUD 300 million as upfront payment at the closure of the transaction, while the balance AUD 94 million to be deferred through a secured instrument," it added.


    Read Also: Strides gets USFDA nod to market laxative Polyethylene Glycol,Electrolytes in US


    In a separate filing, the company said its step-down subsidiary Strides Pharma Inc has entered into an arrangement to acquire 100 per cent stake in US-based generics company Vensun Pharmaceuticals Inc.


    Founded in 2011, Vensun follows an asset-light partner-driven business model to develop products for the US generics markets, Strides Pharma Science said.


    In another filing, the company said its board of directors and its step-down subsidiary Strides Pharma Global Pte Ltd, Singapore, have approved to convert their 50:50 JVs with Vivimed to 100 per cent ownership.


    "Consequently, Strides will acquire balance 50 per cent stake in Vivimed Life Sciences Pvt Ltd, India and its step down subsidiary, Strides Pharma Global Pte, Singapore, will acquire the balance 50 per cent stake in Strides Vivimed Pte Ltd, Singapore to own and operate the erstwhile joint venture companies fully," it added.


    The company also said its step-down subsidiary Strides Pharma Canada Inc has entered into an arrangement to acquire 80 per cent stake in Pharmapar Inc for a consideration of CAD 4 million.


    Founded in 1998, Pharmapar specialises in generic medication to privately insured individuals in Canada, it added.


    Read Also: Strides Pharma Science to get Rs 147 Crore funding for consumer healthcare business

    American Record CorporationArrow PharmaceuticalsBSECanadageneric druggeneric medicationInvestmentlife sciencesStridesStrides PharmaStrides Pharma CanadaStrides Pharma GlobalU SVensun PharmaceuticalsVivimed Life Sciences
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok